KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Leases: 2010-2024

Historic Current Leases for Rigel Pharmaceuticals (RIGL) over the last 12 years, with Dec 2024 value amounting to $285,000.

  • Rigel Pharmaceuticals' Current Leases rose 27.47% to $594,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $594,000, marking a year-over-year increase of 27.47%. This contributed to the annual value of $285,000 for FY2024, which is 58.82% down from last year.
  • Rigel Pharmaceuticals' Current Leases amounted to $285,000 in FY2024, which was down 58.82% from $692,000 recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Current Leases ranged from a high of $9.9 million in FY2021 and a low of $285,000 during FY2024.
  • Moreover, its 3-year median value for Current Leases was $692,000 (2023), whereas its average is $703,333.
  • Its Current Leases has fluctuated over the past 5 years, first increased by 18.55% in 2020, then slumped by 88.55% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Current Leases (Yearly) stood at $8.6 million in 2020, then climbed by 14.74% to $9.9 million in 2021, then plummeted by 88.55% to $1.1 million in 2022, then plummeted by 38.92% to $692,000 in 2023, then tumbled by 58.82% to $285,000 in 2024.